Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 20, 2025 09:15 ET | Source: Longeveron

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron will present and host investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025.
August 13, 2025 16:05 ET | Source: Longeveron

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated...
June 24, 2025 06:30 ET | Source: Longeveron

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).
June 18, 2025 07:00 ET | Source: BPGbio

BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency

BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development.The Company plans to seek guidance in Q3 2025 from...
April 22, 2025 16:05 ET | Source: Longeveron

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

Longeveron issues letter to shareholders highlighting corporate strategy, recent progress and 2025 key priorities and goals.
February 18, 2025 09:25 ET | Source: Longeveron

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

WHO approved generic name laromestrocel for stem cell therapy Lomecel-B, being developed as potential treatment for Alzheimer's disease and HLHS.
October 27, 2024 15:10 ET | Source: Longeveron

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)
October 24, 2024 12:50 ET | Source: Muscular Dystrophy Association

MDA Kickstart Program Receives FDA Rare Pediatric Disease Designation and Orphan Drug Designation for Congenital Myasthenic Syndrome

New York, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) proudly announces that its groundbreaking MDA Kickstart program has received both an FDA Rare Pediatric Disease...
September 09, 2024 09:00 ET | Source: Muscular Dystrophy Association

MDA Kickstart Program Launches for Ultra-Rare Neuromuscular Disease Drug Development

New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...
September 03, 2024 09:00 ET | Source: Longeveron

Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.